Block & Leviton is investigating Immix Biopharma for potential securities law violations. The investigation follows news reports that an executive using the name Richard Graydon was allegedly a Rhode Island most-wanted fugitive named Ronald Fischer operating under a false identity. Immix stated the individual was terminated as of July 17, 2026 for reasons unrelated to his activities at the company and that his short tenure had no material effect on the business. On the day the report circulated, Immix shares fell approximately 10.83%. Investors who purchased Immix Biopharma common stock and have seen their shares fall may be eligible to participate in any potential action to recover losses.
Immix Biopharma IncInvestigation for securities fraud violations following revelation of executive's fugitive identity, causing 10.83% share drop.